HOME PRODUCTS SERVICES COMPANY CONTACT FAQ

Calcitriol (Calcijex)

The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption.

Also Known As:

Calcijex; Rocaltrol; 1,25 Dihydroxycholecalciferol; 1 alpha, 25-dihydroxy-20-epi-Vitamin D3; 1,25(OH)2-20epi-D3; 1,25-dihydroxy-20-epi-Vitamin D3; 20-epi-1alpha,25-dihydroxycholecaliferol; Abbott Brand of Calcitriol; Alphapharm Brand of Calcitriol; Bocatriol; Calcitriol KyraMed; Calcitriol-Nefro; Cryopharma Brand of Calcitriol; Decostriol; Galderma Brand of Calcitriol; Gry Brand of Calcitriol; Hoffmann-La Roche Brand of Calcitriol; Jenapharm Brand of Calcitriol; KyraMed Brand of Calcitriol; Leo Brand of Calcitriol; MC-1288; MC1288; Medice Brand of Calcitriol; Osteotriol; RenaCare Brand of Calcitriol; Renatriol; Roche Brand of Calcitriol; Silkis; Sitriol; Soltriol; Tirocal; 1 alpha, 25 dihydroxy 20 epi Vitamin D3; 1 alpha,25 Dihydroxycholecalciferol; 1 alpha,25 Dihydroxyvitamin D3; 1,25 Dihydroxyvitamin D3; 1,25 dihydroxy 20 epi Vitamin D3; 20 epi 1alpha,25 dihydroxycholecaliferol; Calcitriol Abbott Brand; Calcitriol Alphapharm Brand; Calcitriol Cryopharma Brand; Calcitriol Galderma Brand; Calcitriol Gry Brand; Calcitriol Jenapharm Brand; Calcitriol KyraMed Brand; Calcitriol Leo Brand; Calcitriol Medice Brand; Calcitriol Nefro; Calcitriol RenaCare Brand; Calcitriol Roche Brand; CalcitriolNefro; D3, 1 alpha,25-Dihydroxyvitamin; D3, 1,25-Dihydroxyvitamin; D3, 1,25-dihydroxy-20-epi-Vitamin; Hoffmann La Roche Brand of Calcitriol; KyraMed, Calcitriol; MC 1288; alpha,25-Dihydroxyvitamin D3, 1; 1 alpha,25-Dihydroxycholecalciferol; 1 alpha,25-Dihydroxyvitamin D3; 1,25-Dihydroxycholecalciferol; 1,25-Dihydroxyvitamin D3; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1alpha,3beta,5Z,7E)-

Networked: 2690 relevant articles (218 outcomes, 345 trials/studies) for this Drug, Comments

Relationship Network

Drug Context: Research Results

Experts

1.	Trump, Donald L: 34 articles (09/2010 - 01/2002)
2.	Johnson, Candace S: 33 articles (09/2010 - 01/2002)
3.	Feldman, David: 21 articles (07/2010 - 10/2002)
4.	Beer, Tomasz M: 21 articles (12/2008 - 01/2003)
5.	Muindi, Josephia R: 14 articles (09/2010 - 12/2002)
6.	Krishnan, Aruna V: 13 articles (07/2010 - 07/2003)
7.	Studzinski, George P: 11 articles (07/2010 - 05/2002)
8.	Cozzolino, Mario: 10 articles (05/2010 - 10/2002)
9.	Kutner, Andrzej: 10 articles (09/2009 - 01/2002)
10.	Slatopolsky, Eduardo: 10 articles (02/2008 - 01/2002)

Related Diseases

1.	Secondary Hyperparathyroidism 01/01/1998 - "Although the skeletal lesions of secondary hyperparathyroidism improved in most patients, Z-scores for height decreased from -1.8 +/- 0.32 to -2.0 +/- 0.33, P < 0.01, during intermittent calcitriol therapy. " 01/01/1996 - "Our results confirm the fact that even severe secondary hyperparathyroidism can be successfully treated with oral calcitriol pulse therapy. " 12/01/1995 - "BACKGROUND: Higher doses of calcitriol are effective in lowering markedly elevated 1,84 PTH levels of patients with renal secondary hyperparathyroidism. " 03/01/2000 - "Oral pulsed-dose calcitriol administration has been shown to be effective therapy for patients with secondary hyperparathyroidism. " 10/01/1998 - "In summary, we have shown that 19-nor-1,25(OH)2D2, a new analogue of calcitriol is effective in suppressing PTH in uremic rats with secondary hyperparathyroidism. " Order ALL the reference details at left...
2.	Psoriasis (Pustulosis Palmaris et Plantaris) 04/01/2001 - "Finally, two studies confirm that calcitriol 3 microg g(-1) ointment can be used safely in patients with psoriasis of the head and confirm the high level of clinical efficacy achieved with this compound." 03/01/2001 - "RESULTS: Mean global improvement scores for both groups increased over the 8-week study period; there was a statistically significant difference (P < 0.05) in favour of the calcitriol/UVB combination from week 1. At end-point, 45% of the calcitriol/UVB group showed considerable improvement or clearing of psoriasis, compared with 21% of the control group. " 08/01/2009 - "Calcitriol ointment produces improvement in psoriasis symptoms that is generally similar to the improvement attained with other (except for high potency steroid) topical psoriasis therapies, with a low incidence of adverse events." 08/01/2009 - "Calcitriol was also significantly more effective for the treatment of psoriasis lesions affecting flexural areas. " 08/01/2009 - "In two long-term studies in which patients were treated with calcitriol ointment for a year or longer, calcitriol ointment produced sustained improvement in physician-rated and patient-rated psoriasis severity. " Order ALL the reference details at left...
3.	Hypercalcemia (Milk Alkali Syndrome) 12/01/2007 - "Because of the propensity of bioactive 1,25-dihydroxyvitamin D3 to cause toxic hypercalcemia, considerable effort has been directed to identifying safer drugs while retaining the efficacy of the parent compound. " 11/01/2006 - "Adverse effects of calcitriol administration (specifically ionized hypercalcemia) were not seen in either feline group during either phase of the study over the 3-day evaluation after calcitriol administration was initiated. " 03/01/2004 - "Such concentrations are not achievable in patients when calcitriol is dosed daily due to predictable hypercalcemia and hypercalcuria; however, phase I trials have demonstrated that intermittent dosing allows substantial dose escalation and has produced potentially therapeutic peak calcitriol concentrations. " 06/01/1999 - "Studies to explore approaches to ameliorate the hypercalcemia induced by calcitriol and to explore alternative schedules and interactions with other agents are warranted." 01/01/1996 - "If these studies are confirmed, the use of MgCO3 and a dialysate Mg of 0.6 mg/dl may be considered in selected patients who develop hypercalcemia during treatment with i.v. calcitriol and CaCO3." Order ALL the reference details at left...
4.	Prostatic Neoplasms (Prostate Cancer) 09/01/2005 - "The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth." 06/01/1998 - "The development of calcitriol analogues with decreased calcemic side effects is promising, since such analogues may be even more effective for treating prostate cancer." 01/01/2007 - "Calcitriol (1,25-dihydroxyvitamin D3) and its synthetic analogs (deltanoids) are drugs that have a direct effect on both the skeleton and the invading metastatic cells and, therefore, are considered useful in the treatment of advanced prostate cancer. " 04/01/2009 - "In this study, we investigated whether calcitriol regulated MIS expression in prostate cancer, an action that might contribute to its antiproliferative activity. " 11/01/2006 - "In this study, we elucidate the underlying mechanism by which 1,25-dihydroxyvitamin D3 inhibits p45Skp2 in human LNCaP prostate cancer cells. " Order ALL the reference details at left...
5.	Osteoporosis 10/01/1994 - "In conclusion, as with other drugs currently used in the management of patients with osteoporosis, questions remain to be answered regarding the efficacy of calcitriol relative to other agents, and its tolerability in such patients during the very long term. " 11/01/2004 - "We have shown that calcitriol was an effective treatment for osteoporosis. " 10/01/1996 - "Calcitriol and 1 alpha-OH-D3 may be effective in increasing bone mass and preventing fractures in osteoporosis. " 09/01/2001 - "In conclusion, the efficacy of calcitriol remains unproven as a single agent for the treatment of osteoporosis in men." 12/01/1999 - "OBJECTIVE: To evaluate the efficacy of calcitriol and hormonal replacement therapy (HRT) in the treatment of steroid-induced osteoporosis in hypogonadal women. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	Calcitriol (Calcijex)
2.	Calcium
3.	Vitamin D
4.	hydroxide ion
5.	Parathyroid Hormone (Parathormone)
6.	calcipotriene (calcipotriol)
7.	Cholecalciferol (Vitamin D3)
8.	1-hydroxycholecalciferol (alfacalcidol)
9.	docetaxel (Taxotere)
10.	Hormones

Related Therapies and Procedures

1.	Renal Dialysis (Hemodialysis)
2.	Drug Therapy (Chemotherapy)
3.	Parathyroidectomy
4.	Transplantation (Transplant Recipients)
5.	Continuous Ambulatory Peritoneal Dialysis (CAPD)

blog comments powered by Disqus

TREATMENT OPTIONS
for Secondary Hyperparathyroidism,
Ranking and Evidence

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. Analytic charts allow you and your physicians to see at a glance the treatment options—including new, promising, off-label and experimental.

Free Updates for 1 Year
All 188 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Evidence References
Sample PDF Report on Psoriasis >>

Price:

$8.50 USD & Delivery via PDF download
updates for 1 year

Research Interface PRO

Rapidly retrieve clinical outcome summaries for all evidence of drug efficacy against any disease in seconds. Click "Charts" to view graphs of relative efficacy of all drugs against any known disease. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time. Save hours of search and analysis time:

Two-clicks from Disease to Drug to Evidence: Drill down to full abstract
Enable Experts: Quickly identify key researchers and their publications
Enable FDA Link Generic: Two-clicks to FDA Products/Patents/Generics
Enable Export: All outcome statements and scores exportable to Excel/TSV for automated meta-analysis
Research Network: Explore drug and disease relationships visually
Enable Mobile Interface: Access from your cellphone, iPhone or PDA

Price:

$45.00 USD access via web interface
1 year subscription

Request Bulk Institution License Details >>